The use of direct oral anticoagulants (DOACs), including factor Xa inhibitors, is growing worldwide, but the United States holds the lion’s share of revenue from these brand-name drugs. 2 ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca is currently conducting a study titled ‘Ondexxya for ...

The incidence of composite cardiovascular events, arteriosclerotic disease, congestive heart failure, and cardiovascular death within 5 years was significantly lower in the Xa-I group than in the ...

A previous study, ANNEXA-4, found that in patients on a factor Xa inhibitor with acute major bleeding in any site, 82% had excellent or good hemostatic efficacy at 12 hours.

Source: Cash BD, et al. AIMS65 as an indicator of rebleed and mortality risk in patients using factor Xa inhibitors hospitalized for a gastrointestinal (GI) bleed. Presented at ACG Annual ...

The findings, from the EINSTEIN-DVT study, were announced today by Bayer, the maker of the new factor Xa inhibitor (marketed in collaboration with Johnson & Johnson), which stated in a press ...

Please provide your email address to receive an email when new articles are posted on . Any bleeding event regardless of severity can adversely impact a patient. Factor XI and XIa inhibitors in ...

Factor Xa inhibitors used to treat and prevent thrombotic events may cause or worsen acute major bleeding. New data suggest that bleeding episodes associated with factor Xa inhibitors may be ...

When compared with another factor Xa inhibitor, rivaroxaban (Xarelto; Bayer/Janssen), apixaban (Eliquis; Bristol Myers Squibb) was associated with fewer major hemorrhagic events and similar rates of ...

These include the factor Xa inhibitors rivaroxaban (XARELTO®), apixaban (ELIQUIS®), and edoxaban (SAVAYSA®), as well as dabigatran (Pradaxa®), which targets thrombin. 1 These small, rapidly ...